Treatment with CABLIVI is started in the hospital. After you've completed plasma exchange, sometimes called PEX, your doctor may want you to continue your treatment at home.
Your doctor has options when it comes to your treatment for aTTP/iTTP.* Make sure to ask if you were prescribed CABLIVI.
You, your family, or your caregiver should receive training from your doctor or nurse until you or they feel confident about administering CABLIVI. Let your doctor know if you, your family, or your caregiver are not comfortable doing this or if you have any questions. CABLIVI Patient Solutions offers training on self-injection technique.
After your doctor has decided that you no longer need daily plasma exchange, keep taking CABLIVI until your doctor tells you to stop. Your doctor may decide you need to take CABLIVI for more than 30 days (for up to additional 28 days).
The CABLIVI Patient Solutions program is also available to provide additional support and resources as you move from hospital to home.
There are Instructions For Use that come with CABLIVI, which explain how to administer the medicine. The instructions are also explained in the Administration Training Guide, available in the Support and resources section. It is important that you read through these instructions carefully.
Talk to your doctor before you stop treatment with CABLIVI. Do not stop treatment, even if you start to feel better, as stopping treatment too early could cause you to have another aTTP/iTTP episode.
When your doctor prescribes CABLIVI, you may receive a welcome kit with your prescription that includes these useful resources:
Please review these materials, and talk to your doctor if you have any questions. If you have not received a CABLIVI Welcome Kit, please contact CABLIVI Patient Solutions at 1-855-724-7222 to sign up.
Information about CABLIVI for you and your family.
Information to help with the administration of CABLIVI.
Suggested questions to ask your doctor about treatment with CABLIVI.
Learn more about the support offered through CABLIVI Patient Solutions.
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
Do not take CABLIVI if you've had an allergic reaction to caplacizumab-yhdp or to any of the ingredients in CABLIVI.
Tell your doctor if you have a medical condition including if you have a bleeding disorder. Tell your doctor about any medicines you take, including medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
Talk to your doctor before scheduling any surgery, medical or dental procedure.
CABLIVI can cause severe bleeding. In clinical studies, severe bleeding adverse reactions of nosebleed, bleeding from the gums, bleeding in the stomach or intestines, and bleeding from the uterus were each reported in 1% of subjects. In the post-marketing setting, cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI. Contact your doctor immediately if symptoms of excessive bruising, excessive bleeding, or major bleeding occur. Signs and symptoms of bleeding include: pain, swelling or discomfort, prolonged bleeding from cuts, increased menstrual flow or vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness, or weakness.
You may have a higher risk of bleeding if you have a bleeding disorder (i.e. hemophilia) or if you take other medicines that increase your risk of bleeding such as anti-coagulants and anti-platelet agents.
CABLIVI should be stopped for 7 days before surgery or any medical or dental procedure. Talk to your doctor before you stop taking CABLIVI.
The most common side effects include nosebleed, headache and bleeding gums.
Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of CABLIVI. Call your doctor for medical advice about side effects.
Click here to learn more about Sanofi's commitment to fighting counterfeit drugs.